China's Luqa Pharma Closes $15M B Round for Dermatology/Aesthetic Products
by Richard Daverman, PhD
February 6, 2018 -- Luqa Pharma of Hong Kong closed a $15 million Series B financing round led by Cenova Capital. Luqa, a company that in-licenses dermatology and aesthetic products for China, plans to use the proceeds to expand its China commercial platform and bring its late-stage product portfolio to the market. Founded in 2010, the company specializes in new pharmaceutical and consumer products.